Tibet Aim Pharm. (002826)2025-04-24 13:51Revenue and Profit - The company's revenue for Q1 2025 was ¥148,531,481.16, a decrease of 7.41% compared to ¥160,425,522.45 in the same period last year[4]. - Net profit attributable to shareholders was ¥18,793,851.93, down 32.64% from ¥27,899,079.55 year-on-year[4]. - The basic earnings per share decreased by 33.33% to ¥0.10 from ¥0.15 in the same period last year[5]. - Net profit for the period was CNY 18,928,556.57, down 32.5% from CNY 28,050,728.06 in the previous period[27]. - The net profit attributable to the parent company was 18,793,851.93, a decrease from 27,899,079.55, representing a decline of approximately 32.7% year-over-year[28]. - The total comprehensive income attributable to the parent company was 18,727,675.15, down from 27,944,608.45, indicating a decrease of about 32.9% compared to the previous period[28]. Cash Flow and Operating Activities - Cash flow from operating activities decreased by 42.56% to ¥30,865,875.72 from ¥53,738,523.14 in the same period last year[10]. - Net cash flow from operating activities decreased by 42.56% year-on-year, primarily due to a decrease of CNY 18.185 million in special industrial support funds received[11]. - Cash inflows from operating activities totaled 190,986,029.02, compared to 202,042,040.04 in the previous period, showing a decrease of approximately 5.5%[29]. - The net cash flow from operating activities was 30,865,875.72, down from 53,738,523.14, representing a decline of about 42.6% year-over-year[30]. - The company received cash from sales of goods and services amounting to 178,926,631.19, an increase from 170,015,189.63, reflecting a growth of about 5.3%[29]. - The company paid 38,337,179.15 in cash for goods and services, down from 41,711,034.09, indicating a decrease of approximately 8.5%[30]. - The company reported a cash outflow of 79,324,691.65 for other operating activities, which increased from 60,947,936.52, representing a rise of about 30.0%[30]. Assets and Liabilities - The company's total assets increased by 6.48% to ¥986,510,989.35 from ¥926,469,234.87 at the end of the previous year[5]. - Total assets increased to CNY 986,510,989.35 from CNY 926,469,234.87, representing a growth of 6.5%[24]. - Total liabilities rose to CNY 218,975,807.44 from CNY 180,892,906.43, an increase of 21.1%[25]. - The company's equity attributable to shareholders increased to CNY 760,827,826.19 from CNY 739,003,677.36, a rise of 2.9%[25]. Research and Development - Research and development expenses rose by 342.13% to ¥1,197,352.52 from ¥270,814.38 year-on-year[10]. - R&D expenses increased by CNY 926,500 compared to the same period last year, primarily due to increased investment in research and development[11]. - Research and development expenses increased to CNY 1,197,352.52 from CNY 270,814.38, a significant increase of 341.5%[27]. Financial Management and Investments - The company reported a significant increase in short-term borrowings by 54.69%, amounting to ¥35,300,443.10 compared to ¥22,819,445.17 previously[9]. - The company received government subsidies amounting to ¥10,223,089.90, primarily related to industry support funds[7]. - Financial expenses increased by CNY 592,900 compared to the same period last year, mainly due to a decrease in interest income from current deposits[11]. - Investment income increased by CNY 228,100 compared to the same period last year, mainly due to increased income from financial product investments[11]. - The company has entrusted CNY 20 million in financial management, with all funds remaining unexpired[18]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,855[13]. - The largest shareholder, Gao Fan, holds 25.59% of the shares, totaling 48,800,382 shares[13]. - The company completed the first grant registration of the 2024 restricted stock incentive plan, granting 3.44 million shares at a price of CNY 6.45 per share[16].